ArticleOrphanet journal of rare diseases2020
Clinical features of a Chinese female nongestational choriocarcinoma cohort: a retrospective study of 37 patients.
Article in Orphanet journal of rare diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 24 citations in OpenAlex.
- Ovarian Tumor Biomarkers: Correlation Between Tumor Type and Marker Expression, and Their Role in Guiding Therapeutic Strategies.International journal of molecular sciences · 2025Review
- Precision Diagnosis and Individualized Therapy of Non-Gestational Choriocarcinoma Invading the Corpus Uteri and Cervix: A Case Report and Literature Review.Cancer reports (Hoboken, N.J.) · 2025Review
- A rare case of pure non-gestational ovarian choriocarcinoma: Diagnostic mimicry and management strategies.Oncoscience · 2025Article
- Clinical and Imaging Characteristics of Non-Gestational Ovarian Choriocarcinoma: A Case Report.Current medical imaging · 2025Article
- Article
- Non-gestational Choriocarcinoma of the Ovary: A Report of a Rare Case From Saudi Arabia.Cureus · 2024Article
- Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model.BMC cancer · 2023Article
- Article
- Primary ovarian choriocarcinoma occurring in a postmenopausal woman: A case report.World journal of clinical cases · 2023Article
- Non-gestational uterine choriocarcinoma inside a leiomyoma: importance of early suspicion in prognosis.BMJ case reports · 2022Article
- Non-Gestational Ovarian Choriocarcinoma: A Rare Ovarian Cancer Subtype.Diagnostics (Basel, Switzerland) · 2022Review
- Outcomes in gestational and non-gestational choriocarcinoma: A retrospective cohort study with nomograms and web tools.Women's health (London, England)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChoriocarcinoma is a rare malignant neoplasm, which is classified as either gestational choriocarcinoma or nongestational choriocarcinoma. The purpose of this study was to examine the clinical characteristics of Chinese female nongestational choriocarcinoma patients and discuss our experience in treating this rare disease.
resultsWe conducted a single-center retrospective study on a sample of 37 nongestational choriocarcinoma patients who were diagnosed and treated at Peking Union Medical College Hospital from March 1982 to March 2020. Their demographic, clinical, laboratory, and therapeutic data were collected. Detailed information was available for all 37 individuals in our sample. The primary lesions included 34 in the ovaries, 2 in the pituitary and 1 in the stomach. The median age of onset was 22 years, and the median follow-up period spanned 41 months. The lungs (40.5%) were the most commonly observed metastatic site. All subjects were treated with surgery and multidrug chemotherapies, and a median of 4.0 courses was required to achieve complete remission. The overall complete response rate, relapse rate, and 3-year and 5-year survival rates were 81.1%, 16.7%, 80.0%, and 75.5%, respectively.
conclusionsNongestational choriocarcinoma can be managed well using surgery and multidrug chemotherapies, but the overall outcome of nongestational choriocarcinoma is still worse than that of gestational choriocarcinoma. Mixed nongestational choriocarcinoma seems to have similar therapeutic outcomes as pure tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.